期刊文献+

异基因外周血干细胞输注后24小时内发热病因分析 被引量:2

Etiological analysis of fever in the first 24 hours following allogeneic peripheral stem cell transfusion
原文传递
导出
摘要 目的探讨接受异基因外周血干细胞输注后24h内患者新出现发热的发生率和病因,并分析相关的危险因素。方法回顾性分析北京大学人民医院血液病研究所2009年10月至2010年8月异基因造血干细胞移植治疗的114例患者中,输注外周血干细胞24h内新出现发热患者的临床资料。应用多因素logistic回归分析输注相关性发热的危险因素。结果114例异基因外周血干细胞输注后24h内共有32例(28.1%)患者出现发热,均为人类白细胞抗原(HLA)配型不相合的亲缘间移植。最高体温平均值为39.0(37.6-40.4)oC;出现发热的中位时间为输注后的2.5(0-18.0)h;体温达到峰值的中位时间为输注后7.8(3.5-23.0)h。发热病因分析:6例为感染性病因;26例排除溶血后归为输注相关性发热。多因素分析发现女性供者及供者采集当日外周血白细胞计数高是输注相关性发热的危险因素。结论异基因外周血细胞输注后24h内新出现的发热均发生在HLA配型不相合亲属间移植患者,大多数与输注关系明显,无明确感染灶,其危险因素是女性供者及供者采集当日外周血白细胞高计数。 Objective To investigate the incidence and pathogenesis of fever within the first 24 hours following allogeneic peripheral stem cell transfusion and to analyze the associated risk factors. Methods Totally 114 patients received allogeneie hematopoietic stem cell transplantation (allo-HSCT) between October 2009 and August 2010 were enrolled and clinical data of febrile patients within 24 hours following peripheral stem cell transfusion were retrospectively analyzed. Multivariate logistic regression analysis was performed to identify the risk factors for transfusion related fever. Results Thirty-two (28. 1% ) out of the 114 patients had a fever within 24 hours after allo-HSCT. All of them were human leukocyte antigen (HLA) mismatch transplantation. The median time of the temperature elevated was 2. 5 (0-18.0) hours after the infusion with a median time of the peak of 7. 8(3.5-23.0) hours after the infusion. Fever was attributed to definite infection in 6 patients and no definite infection in the remaining 26 patients. None of them were hemolytic, which was attributed to transfusion related fever. Multivariate analysis showed that female donor and high count of peripheral leukocyte of donor peripheral blood were significant predictors for transfusion related fever. Conclusions Most of post-infusion fever within 24 hours after HLA mismatch related transplantation has no identifiable infectious focus. The risk factors for transfusion related fever are female donor and high number of peripheral leukocyte of donor blood.
出处 《中华内科杂志》 CAS CSCD 北大核心 2012年第3期179-183,共5页 Chinese Journal of Internal Medicine
基金 国家杰出青年科学家基金(30725038) 卫生部公益基金(200802027)
关键词 发热 感染 外周血干细胞输注 Fever Infection Peripheral blood stem cell transfusion
  • 相关文献

参考文献10

  • 1Barton JC.Nonhemolytic,noninfectious transfusion reactions.Semin Hematol,1981,18:95-121.
  • 2Rutledge R,Sheldon GF,Collins ML.Massive transfusion.Crit Care Clin,1986,2:791-805.
  • 3Fenwick JC,Cameron M,Naiman SC,et al.Blood transfusion as a cause of leucocytosis in critically ill patients.Lancet,1994,344:855-856.
  • 4Syme R,Bewick M,Stewart D,et al.The role of depletion of dimethyl sulfoxide before autografting:on hematologic recovery,side effects,and toxicity.Biol Blood Marrow Transplant,2004,10:135-141.
  • 5石红霞,黄晓军,王峰容,韩伟,刘代红,江滨,陆道培.急性白血病患者粒细胞缺乏时发热的经验治疗[J].中国抗感染化疗杂志,2004,4(4):209-212. 被引量:6
  • 6Sachs UJ,Wasel W,Bayat B,et al.Mechanism of transfusionrelated acute lung injury induced by HLA class Ⅱ antibodies.Blood,2011,117:669-677.
  • 7Bux J.Antibody-mediated(immune)transfusion-related acute lung injury.Vox Sang,2011,100:122-128.
  • 8Rutella S.Granulocyte colony-stimulating factor for the induction of T-cell tolerance.Transplantation,2007,84(1 Suppl):S26-30.
  • 9Bojanic I,Cepulic BG,Mazic S,et al.Toxicity related to autologous peripheral blood haematopoietic progenitor cell infusion is associated with number of granulocytes in graft,gender and diagnosis of multiple myeloma.Vox Sang,2008,95:70-75.
  • 10Imoto S,Araki N,Shimada E,et al.Comparison of acute nonhaemolytic transfusion reactions in female and male patients receiving female or male blood components.Transfus Med,2007,17:455-465.

二级参考文献8

  • 1[1]Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer[J]. Clin Infect Dis, 2002, 34:730-751
  • 2[4]Hathorn JW, Lyke K. Empirical treatment of febrile neutropenia: evolution of current therapeutic approachcs[J]. Clin Infect Dis, 1997, 24 (Suppl2): S256-265
  • 3[5]Cometta A, Glauser MP. Empiric antibiotic nonotherapy with carbapenemsin febrile neutropenia: a review[J]. J Chemother,1996, 8:375-381
  • 4[6]Shah PM, Heller A, Fuhr HG, et al. Empirical monotherapy with meropenem versus imipenem/cilastatin for febrile episodes in neutropenic patients[J]. Infection 1996, 24:480-484
  • 5[7]Norrby SR, Gildon KM. Safety profile of meropcnem: a review of nearly 5 ,000 patients treated withmeropenem[J]. ScandJ In feet Dis, 1999, 31:3-10
  • 6[9]Vandercam B, Gerain J, Humblet Y, et al. Meropenem versus ceftazidime as empirical monotherapy for febrile neutropenic cancer patients[J]. Ann Hematol, 2000, 79:152-157
  • 7李家泰,李耘,王进,中国细菌耐药监测研究组.中国医院和社区获得性感染革兰阳性球菌耐药性监测研究[J].中华医学杂志,2003,83(5):365-374. 被引量:198
  • 8陈民钧,王辉,中国医院内病原菌耐药监测网.中国重症监护病房革兰阴性菌耐药性连续7年监测研究[J].中华医学杂志,2003,83(5):375-381. 被引量:504

共引文献5

同被引文献36

  • 1Itzykson R, Fenaux P. Optimizing hypomethylating agents in myelodysplastic syndromes[J]. Curr Opin Hematol, 2012, 19 (2): 65-70.
  • 2Kantarjian H, Oki Y, Garcia- Manero G, et al. Results of a randomized study of 3 schedules of low- dose decitabine in higher- risk myelodysplastic syndrome and chronic myelomonocytic IeukemiaJ J]. Blood, 2007, 109( I): 52-57.
  • 3Steensma DP, Baer MR, SlackJL, et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trialJ J].J Clin Oncol, 2009, 27 (23): 3842-3848.
  • 4National Institutes of Health, National Cancer Institute. Com?mon Terminology Criteria for Adverse Events (CTCAE) Ver?sion 4.0[S]. Washington DC, United States Department of Health and Human Services, 2009.
  • 5Liibbert M, Suciu S, Baila L, et al. Low- dose decitabine versus best supportive care in elderly patients with intermediate- or high- risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group[J].J Clin Oncol, 2011, 29( 15): 1987-1996.
  • 6LeeJH, lang IH, Park I, et al. A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome[J]. Haematologica, 2011, 96 (10): 1441-1447.
  • 7Kantarjian H, Issa IP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase ill randomized study[IJ. Cancer, 2006, 106 ( 8 ) : 1794-803.
  • 8LeeJH, Lee KH, LeeJH, et al. Decreased incidence of febrile episodes with antibiotic prophylaxis in the treatment of decitabine for myelodysplastic syndromeJ J]. Leuk Res, 2011, 35 (4): 499-503.
  • 9Horowitz MM.Uses and Growth of Hematopoietic Cell Transplantation.Thomas' Hematopoietic Cell Ttransplantation,3rd ed[M].Hoboken,NJ:Wiley-Blackwell Publishing,2004:9-15.
  • 10Ford CE,Hamerton JL,Barnes DW,et al.Cytological identification of radiation-chimaeras[J].Nature,1956,177(4506):452-454.

引证文献2

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部